Publications (3)6.37 Total impact
-
Article: Phosphorylation of Mps1 by BRAF(V600E) prevents Mps1 degradation and contributes to chromosome instability in melanoma.
[show abstract] [hide abstract]
ABSTRACT: Activating BRAF mutations that deregulate the mitogen-activated protein kinase (MAPK) pathway commonly occur in cancer. BRAF(V600E) induces centrosome amplification and spindle abnormalities that result in aneuploidy. We find modification of Mps1 is critical for contributing to centrosome amplification and chromosome instability induced by BRAF(V600E). Phosphorylation of Mps1 at residue S281 induced by BRAF(V600E) stabilizes Mps1 protein by preventing its ubiquitination by APC/C and subsequent degradation, allowing the non-degraded protein to accumulate at centrosomes. Cells in which endogenous Mps1 was replaced with a phospho-mimetic Mps1 mutant are viable but amplify centrosomes and missegregate chromosomes frequently. Importantly, analysis of tumor micro arrays revealed that phospho-MAPK and S281-phosphorylated Mps1 were highly correlated in human melanoma tissues, implying that MAPK contributes to defects in the degradation of Mps1 in situ. We propose that continuously activated BRAF(V600E) signaling may be a possible mechanism for the deregulation of Mps1 stability and kinase activity in human tumors, and that persistent phosphorylation of Mps1 through BRAF(V600E) signaling is a key event in disrupting the control of centrosome duplication and chromosome stability that may contribute to tumorigenesis. Our findings raise the possibility that targeting the oncogenic BRAF and S281-phosphorylated Mps1, especially when used in combination could potentially provide great therapeutic opportunities for cancer treatment.Oncogene advance online publication, 19 March 2012; doi:10.1038/onc.2012.94.Oncogene 03/2012; · 6.37 Impact Factor -
Article: Antithrombotic and thrombolytic activities of Agkisacutacin, a snake venom proteinase, in experimental models.
[show abstract] [hide abstract]
ABSTRACT: The antithrombotic and thrombolytic activities of Agkisacutacin (Agk), a component isolated from Agkistrodon acutus, were determined in vitro and in vivo. The models employed included Chandler's model, arterio-venous shunt model and pulmonary embolus model. The effects of Agkisacutacin on coagulation, plasma fibrinogen and platelet aggregation induced by collagen, adenosine diphosphate (ADP) and thrombin were also investigated. The results showed that Agkisacutacin can significantly inhibit thrombus formation in Chandler's and arterio-venous shunt models, and accelerate thrombolysis of pulmonary emboli in rats. The data suggested that Agkisacutacin possessed antithrombotic and thrombolytic activities. Agkisacutacin was also partial characterized.General Pharmacology 11/2000; 35(4):179-87. -
Article: Antithrombotic effects of low-molecular-weight heparin calcium (LMWH-Ca) in experimental models.
[show abstract] [hide abstract]
ABSTRACT: The antithrombotic activity of low-molecular-weight heparin calcium (LMWH-Ca) was studied in venous and arterial thrombosis models, arterial thrombosis model in rats, arterio-venous shunt model and venous thrombosis model in rabbits. The data showed that LMWH-Ca reduced thrombus formation in a dose-dependent manner. It suggests that LMWH-Ca is a potent antithrombotic agent for venous thrombosis, and also may be a beneficial therapeutic agent in arterial thrombosis.General Pharmacology 09/1999; 33(2):207-11.
